<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sparsentan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sparsentan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sparsentan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140851" href="/d/html/140851.html" rel="external">see "Sparsentan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57889488"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Distribution program:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Because of the risks of hepatotoxicity and birth defects, sparsentan is available only through a restricted program called the Filspari REMS. Under the REMS, prescribers, patients, and pharmacies must enroll in the program.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Some endothelin receptor antagonists have caused elevations of aminotransferases, hepatotoxicity, and liver failure. In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3 × the ULN have been observed in up to 2.5% of sparsentan-treated patients, including cases confirmed with rechallenge. Measure transaminases and bilirubin before initiating treatment and monthly for the first 12 months, and then every 3 months during treatment. Interrupt treatment and closely monitor patients who develop aminotransferase elevations more than 3 × ULN. Sparsentan should generally be avoided in patients with elevated aminotransferases (&gt;3 × ULN) at baseline because monitoring for hepatotoxicity may be more difficult and these patients may be at increased risk for serious hepatotoxicity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Embryo-Fetal Toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Sparsentan can cause major birth defects if used by pregnant patients based on animal data. Therefore, pregnancy testing is required before the initiation of treatment, during treatment, and 1 month after discontinuation of treatment with sparsentan. Patients who can become pregnant must use effective contraception before the initiation of treatment, during treatment, and for 1 month after discontinuation of treatment with sparsentan.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57950871"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Filspari</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57889491"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiotensin II Receptor Blocker;</li>
<li>
                        Endothelin Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F57967971"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0e8695a-ab23-4579-8a2a-e35dd8656c8d">IgA nephropathy, primary, nonvariant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>IgA nephropathy, primary, nonvariant:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider as an alternative nonimmunosuppressive therapy in patients at high risk of chronic kidney disease progression (eg, urine protein-to-creatinine ratio of ≥1.5 g/g) despite receiving optimized therapy (eg, maximally tolerated angiotensin converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]) for at least 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barratt.1','lexi-content-ref-Cattran.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barratt.1','lexi-content-ref-Cattran.1','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Safety:</b> Prior to initiating therapy, discontinue renin-angiotensin-aldosterone system inhibitors (eg, ACE inhibitors and ARBs), endothelin receptor antagonists, and aliskiren. Consider adjusting or eliminating other medications that may decrease blood pressure in patients at risk for hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 mg once daily for 14 days, then increase to target dose of 400 mg once daily if tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Interruption of therapy:</i> Consider restarting at 200 mg once daily after a treatment interruption. After 14 days, increase to target dose of 400 mg once daily if tolerated.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57967973"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustments provided in the manufacturer’s labeling; however, need for dosage adjustment unlikely as no clinically significant differences in pharmacokinetics were observed in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney injury during treatment:</b> Consider withholding or discontinuing in patients who develop a significant decrease in kidney function.</p></div>
<div class="block doha drugH1Div" id="F57967974"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment <i>prior</i> to treatment:</b> Avoid use in patients with any hepatic impairment (Child-Pugh class A to C) due to the potential risk of serious liver injury.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Aminotransferase elevations <i>during</i> treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ALT or AST &gt;3 times and ≤8 times the ULN:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Confirm elevation with a repeat measure. If confirmed, interrupt treatment and monitor aminotransferase levels and bilirubin at least weekly (INR periodically as needed) until levels return to pretreatment values and patient is asymptomatic. Then may consider reinitiating therapy at 200 mg once daily with close monitoring, with reassessment of hepatic enzyme levels and bilirubin within 3 days.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Do not</b> resume treatment if patient has experienced clinical symptoms of hepatotoxicity or the following occurs with no other identifiable cause:</p>
<p style="text-indent:-2em;margin-left:8em;">ALT or AST &gt; 3 times ULN <b>and</b> total bilirubin &gt;2 times ULN <b>or</b> INR &gt;1.5.</p>
<p style="text-indent:-2em;margin-left:8em;">ALT or AST &gt;3 times ULN with symptoms of fatigue, nausea, vomiting, right upper quadrant pain/tenderness, fever, rash, and/or eosinophilia (&gt;5% eosinophils).</p>
<p style="text-indent:-2em;margin-left:8em;">ALT or AST &gt;5 times ULN for more than 2 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;margin-right:0em;">
<i>ALT or AST &gt;8 times the ULN: </i>Permanently discontinue treatment if no other cause for elevation identified.</p></div>
<div class="block dot drugH1Div" id="F57967975"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Fluid retention: </b>Determine underlying cause and evaluate potential need to initiate or modify diuretic treatments prior to reducing the dose of sparsentan.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia:</b> Reducing sparsentan dose or discontinuing sparsentan therapy may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension (despite elimination or reduction of other antihypertensives):</b> Consider reducing sparsentan dose or interrupting sparsentan therapy. Can consider reinitiating once BP is stabilized.</p></div>
<div class="block doe drugH1Div" id="F57967972"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58633589"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute kidney injury</b> (AKI) has been reported with sparsentan. In one clinical study, AKI was defined by decreases in serum creatinine between outpatient visits and rarely led to sparsentan discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37015244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37015244'])">Ref</a></span>). Increases in serum creatinine secondary to angiotensin II receptor blockers usually stabilize within 20% to 30% from baseline and are expected; additional increases may indicate renal artery stenosis or volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25018935','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25018935','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; angiotensin II receptor blockade inhibits efferent arteriolar vasoconstriction, lowering glomerular filtration pressure which can lead to a modest reduction in glomerular filtration rate (GFR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; initial reduction in GFR generally occurs within 4 weeks of initiation and then stabilizes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Volume depletion</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Severe congestive heart failure</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Concurrent diuretic, renin-angiotensin system inhibitor, and/or nonsteroidal anti-inflammatory use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Chronic kidney disease</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>•</i> Patients with low renal blood flow (eg, renal artery stenosis) whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum alanine aminotransferase</b> (ALT) and <b>increased serum aspartate aminotransferase</b> (AST) have been reported with sparsentan. Increased ALT and AST were ≥3 times the ULN, asymptomatic, and reversible. Although some endothelin receptor antagonists have caused hepatotoxicity and liver failure, there were no reports with sparsentan in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Elevated transaminases (&gt;3 times the ULN) at baseline</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia</b> has been reported with sparsentan. Most reported cases of hyperkalemia were mild to moderate and did not require therapy discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37015244','lexi-content-ref-30361325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37015244','lexi-content-ref-30361325'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to pharmacologic action; angiotensin II receptor blockade prevents angiotensin II from binding to the adrenal receptor and interferes with generation of angiotensin II within the adrenal cortex, decreasing aldosterone release and impairing kidney potassium excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1855477','lexi-content-ref-21883995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1855477','lexi-content-ref-21883995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Generally occurs within 1 week of angiotensin receptor blocker initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24262001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24262001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Advanced kidney disease</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Baseline elevated potassium (≥5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Concurrent use of medications known to decrease renin and aldosterone (eg, direct renin inhibitors, nonsteroidal anti-inflammatory drugs, cyclosporine, tacrolimus, beta-blockers, sulfamethoxazole/trimethoprim, azole antifungals) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i> Concomitant use of potassium supplements, potassium-sparing diuretics, and/or potassium-containing salt substitutes</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57905675"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (14%; including orthostatic hypotension), peripheral edema (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (13%)<span class="lexi-table-link-container"> (<a aria-label="Hyperkalemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperkalemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperkalemia')">table 1</a>)</span><span class="table-link" style="display:none;">Hyperkalemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperkalemia" frame="border" id="lexi-content-hyperkalemia" rules="all">
<caption style="text-align:center;">
<b>Sparsentan: Adverse Reaction: Hyperkalemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sparsentan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Irbesartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sparsentan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Irbesartan)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (3%; including increased serum alanine aminotransferase and increased serum aspartate aminotransferase &gt;3 × ULN)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Transaminases table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-transaminases" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-transaminases')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Transaminases</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Transaminases" frame="border" id="lexi-content-increased-serum-transaminases" rules="all">
<caption style="text-align:center;">
<b>Sparsentan: Adverse Reaction: Increased Serum Transaminases</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sparsentan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Irbesartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sparsentan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Irbesartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Including increased serum alanine aminotransferase and increased serum aspartate aminotransferase &gt;3 × ULN</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (4%)<span class="lexi-table-link-container"> (<a aria-label="Acute Kidney Injury table link" class="lexi-table-link" data-table-id="lexi-content-acute-kidney-injury" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-acute-kidney-injury')">table 3</a>)</span><span class="table-link" style="display:none;">Acute Kidney Injury</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Acute Kidney Injury" frame="border" id="lexi-content-acute-kidney-injury" rules="all">
<caption style="text-align:center;">
<b>Sparsentan: Adverse Reaction: Acute Kidney Injury</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sparsentan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Irbesartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sparsentan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Irbesartan)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">202</p></td></tr></tbody></table></div>
<div class="block coi drugH1Div" id="F57889494"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Pregnancy; coadministration with angiotensin receptor blockers, endothelin receptor antagonists, or aliskiren.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block foc drugH1Div" id="F57950872"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Filspari: 200 mg, 400 mg</p></div>
<div class="block geq drugH1Div" id="F57950870"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57989947"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Filspari Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $427.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">400 mg (per each): $427.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57967978"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Swallow tablets whole with water prior to morning or evening meal. Maintain the same dosing pattern in relationship to meals.</p></div>
<div class="block meg drugH1Div" id="F57960713"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F216403s000lbl.pdf%23page%3D22&amp;token=X2Kzzhw39jcv8z3LJEHiyLcHsdzZoiVIMcq041T4kkmjnJ4XMXYqRxzUMD49DpxSLitLqv9n1pKWuUUNdWZbpKQqXaUpFlMONkvO17BKoyYJfU8NsskQmJvCeyEt6blc&amp;TOPIC_ID=140820" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf#page=22</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F57889493"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>IgA nephropathy, primary, nonvariant (alternative agent): </b>To reduce proteinuria in adults with primary IgA nephropathy (IgAN) at high risk of chronic kidney disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g. <b>Note:</b> Approved under accelerated approval based upon reduction in proteinuria. It has not been established whether sparsentan slows kidney function decline in patients with IgAN.</p></div>
<div class="block cyt drugH1Div" id="F57922682"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP2B6 (weak)</p></div>
<div class="block dri drugH1Div" id="F57922679"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Sparsentan may enhance the adverse/toxic effect of Aliskiren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Receptor Blockers may diminish the therapeutic effect of Angiotensin II.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Sparsentan may enhance the adverse/toxic effect of Angiotensin II Receptor Blockers. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Sparsentan may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Sparsentan. Management: Administer sparsentan 2 hours before or 2 hours after antacids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors): Sparsentan may increase the serum concentration of BCRP/ABCG2 Substrates (Clinically Relevant with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: Sparsentan may increase the serum concentration of Berotralstat. Berotralstat may increase the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Weak) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Sparsentan may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers): Sparsentan may decrease the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Sparsentan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Sparsentan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Sparsentan.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sparsentan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Endothelin Receptor Antagonists: Sparsentan may enhance the adverse/toxic effect of Endothelin Receptor Antagonists. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Sparsentan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Sparsentan.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: Sparsentan may increase the serum concentration of Lefamulin. Lefamulin may increase the serum concentration of Sparsentan. Specifically, the use of oral lefamulin may increase sparsentan concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Initiate lithium at lower doses in patients receiving an angiotensin II receptor blocker (ARB). Consider lithium dose reductions in patients stable on lithium therapy who are initiating an ARB. Monitor lithium concentrations closely when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin II Receptor Blockers. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Sparsentan may increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57967956"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use; verify the patient is not pregnant prior to treatment initiation in patients who could become pregnant. A negative pregnancy test is required prior to treatment initiation, monthly during treatment, and 1 month after the last dose of sparsentan in patients who could become pregnant. Additional pregnancy testing is also recommended if menses is delayed or whenever pregnancy is suspected.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during therapy and for 1 month after the last sparsentan dose. Options for effective birth control include one of the following (also refer to prescribing information):</p>
<ul>
<li>
<p style="text-indent:0em;">Option 1: Copper IUD, levonorgestrel IUD, tubal sterilization, <b>or</b> progesterone implant.</p></li>
<li>
<p style="text-indent:0em;">Option 2: Oral estrogen/progestin contraceptive, transdermal estrogen/progesterone patch, vaginal ring, <b>or</b> progesterone injection, <b>and</b> use of a male condom, diaphragm with spermicide <b>or</b> cervical cap with spermicide.</p></li>
<li>
<p style="text-indent:0em;">Option 3: Diaphragm with spermicide <b>or</b> cervical cap with spermicide <b>and</b> use of a male condom.</p></li>
<li>
<p style="text-indent:0em;">Option 4: Partner’s vasectomy <b>and</b> use of a male condom, diaphragm with spermicide, cervical cap with spermicide, oral estrogen/progestin contraceptive, transdermal estrogen/progesterone patch, vaginal ring, <b>or</b> progesterone injection.</p></li></ul></div>
<div class="block pri drugH1Div" id="F57967957"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to sparsentan may cause fetal harm. Use is contraindicated in patients who are pregnant.</p></div>
<div class="block brc drugH1Div" id="F57967958"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sparsentan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant (including hypotension), breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F57967980"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Periodically monitor BP, serum creatinine, serum potassium, signs and symptoms of fluid retention or hepatotoxicity (eg, nausea, vomiting, right upper quadrant pain/tenderness, fatigue, anorexia, jaundice, dark urine, fever, itching).</p>
<p style="text-indent:-2em;margin-left:2em;">ALT, AST, and bilirubin: Prior to treatment initiation (do not initiate treatment in patients with ALT or AST &gt;3 times the ULN), monthly for the first 12 months after initiation or restarting after treatment interruption for aminotransferase elevations, and every 3 months thereafter.</p>
<p style="text-indent:-2em;margin-left:2em;">Pregnancy testing (in patients who can become pregnant): A negative pregnancy test is required prior to treatment initiation, monthly during treatment, and 1 month after the last dose of sparsentan. Additional pregnancy testing is also recommended if menses is delayed or whenever pregnancy is suspected.</p></div>
<div class="block pha drugH1Div" id="F57967962"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sparsentan is an endothelin type A receptor (ET<sub>A</sub>R) and angiotensin II type 1 receptor (AT<sub>1</sub>R) antagonist. Endothelin-1 and angiotensin II are thought to contribute to the pathogenesis of immunoglobulin A nephropathy (IgAN) via these receptors, and sparsentan has a high affinity for them, with a greater than 500-fold selectivity over the endothelin type B and angiotensin II subtype 2 receptors.</p></div>
<div class="block phk drugH1Div" id="F57967963"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 61.4 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Cytochrome P450 3A.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 9.6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~3 hours (range: 2 to 8 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: ~80% (9% as unchanged drug); Urine: 2%.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance (steady state): 5.11 L/hour.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Barratt.1">
<a name="Barratt.1"></a>Barratt J, Rovin B, Wong MG, et al; PROTECT Investigators. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. https://www.kireports.org/article/S2468-0249(23)01195-6/fulltext. Published online March 3, 2023. Accessed March 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018935">
<a name="25018935"></a>Chapter 10: Immunoglobulin A nephropathy. <i>Kidney Int Suppl (2011)</i>. 2012;2(2):209-217. doi:10.1038/kisup.2012.23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/25018935/pubmed" id="25018935" target="_blank">25018935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Travere.1">
<a name="Travere.1"></a>Filspari (sparsentan) [prescribing information]. San Diego, CA: Travere Therapeutics, Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37015244">
<a name="37015244"></a>Heerspink HJL, Radhakrishnan J, Alpers CE, et al; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. <i>Lancet</i>. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/37015244/pubmed" id="37015244" target="_blank">37015244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1855477">
<a name="1855477"></a>Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. <i>Endocrinology</i>. 1991;129(2):823-31. doi:10.1210/endo-129-2-823<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/1855477/pubmed" id="1855477" target="_blank">1855477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23176216">
<a name="23176216"></a>Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. <i>Curr Pharm Des</i>. 2013;19(17):3033-42. doi:10.2174/1381612811319170009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/23176216/pubmed" id="23176216" target="_blank">23176216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295051">
<a name="15295051"></a>Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>N Engl J Med</i>. 2004;351(6):585-592. doi:10.1056/NEJMra035279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/15295051/pubmed" id="15295051" target="_blank">15295051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24262001">
<a name="24262001"></a>Park IW, Sheen SS, Yoon D, et al. Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring? <i>J Clin Pharm Ther</i>. 2014;39(1):61-68. doi:10.1111/jcpt.12109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/24262001/pubmed" id="24262001" target="_blank">24262001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883995">
<a name="21883995"></a>Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cardiovasc Ther</i>. 2012;30(3):e156-e166. doi:10.1111/j.1755-5922.2010.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/21883995/pubmed" id="21883995" target="_blank">21883995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695383">
<a name="18695383"></a>Ryan MJ, Tuttle KR. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury? <i>Curr Opin Nephrol Hypertens</i>. 2008;17(5):443-449. doi:10.1097/MNH.0b013e32830a9606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/18695383/pubmed" id="18695383" target="_blank">18695383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11602506">
<a name="11602506"></a>Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <i>Circulation</i>. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/11602506/pubmed" id="11602506" target="_blank">11602506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30361325">
<a name="30361325"></a>Trachtman H, Nelson P, Adler S, et al; DUET Study Group. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. <i>J Am Soc Nephrol</i>. 2018;29(11):2745-2754. doi:10.1681/ASN.2018010091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/30361325/pubmed" id="30361325" target="_blank">30361325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10619572">
<a name="10619572"></a>Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? <i>Am J Hypertens</i>. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sparsentan-drug-information/abstract-text/10619572/pubmed" id="10619572" target="_blank">10619572</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 140820 Version 27.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
